Case Study:
Physician Segmentation and Marketing Actions
Physician Segmentation and Marketing Actions
In this case study the client discovered that the drug was not being used as it should as directed in the clinical guidelines for superior patient outcomes, in some physician segments. So they wanted to find out if there was a way to not only understand the segments but also to offer some sales and marketing levers that could influence the physicians to switch segments.
The Client Problem
• Oncology brand requiring maintenance therapy after induction
• Significant number of physicians not using maintenance preferring to treat at progression
• Oncologists tended to fall into 3 segments
• Insignificant switch between segments
The Solution
• Use big data and AI to:
◦ Understand which physicians fall into which segment
◦ Understand which influences lead individual physicians to make the maintenance choices they do, and therefore why they are in a specific segment
◦ Understand how to influence a dynamics between segments, in particular health care providers who are always using, selectively using and never using.
◦ Identify appropriate interventions that can be utilized by the sales and marketing teams to assist physicians in fully supporting the use of the maintenance treatment for patients where indicated.
◦ Map KOLs who believe in maintenance and utilize them and their network to influence non-believers
The Outcome
• 37% increase in physicians using maintenance treatment within 6 months
To achieve these kinds of results, contact Eularis today.
Latest News
Read our latest blogs here.
We Have AI Initiatives. But, Do We Have a Strategy?
Every week, I speak with executives who tell me the same thing with the same mixture of pride and quiet unease: “We’re investing heavily in
Pharma’s Patent Cliff is Here. Why AI Strategy Matters Now More Than Ever.
The pharmaceutical industry is entering a decisive period. Over the next several years, many of its most valuable brands will lose exclusivity, putting a substantial
The Hidden Cost of Having No AI Strategy (Spoiler: It’s Not What You Think)
In the past few years, almost 70% of biopharma companies have initiated AI initiatives. Yet, fewer than 20% report a cohesive AI strategy at the